Did you know that June 14th was World Blood Donor Day? Recently, REGENXBIO partnered with the American Red Cross to host our second annual blood drive! These blood drives have the power to save lives and make a real impact on patients in need, a mission close to our hearts. Inspired to donate? Find a local blood drive here: https://lnkd.in/ebwyUut
REGENXBIO Inc.
Biotechnology Research
Rockville, Maryland 31,928 followers
Seeking to improve lives through the curative potential of gene therapy.
About us
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
- Website
-
https://www.regenxbio.com
External link for REGENXBIO Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Rockville, Maryland
- Type
- Public Company
- Founded
- 2008
- Specialties
- Biotechnology, Biopharmaceuticals, and Gene Therapy
Locations
-
Primary
Get directions
9804 Medical Center Dr
Rockville, Maryland 20850, US
Employees at REGENXBIO Inc.
Updates
-
It was great attending Parent Project Muscular Dystrophy’s (PPMD) 30th Annual Conference last week in Orlando to connect and catch up with families, researchers, providers, and fellow industry colleagues. Dr. Naz Dastgir, Clinical Development Lead for our Duchenne program, shared an update on our RGX-202 program and participated in a panel discussion about clinical trials and the development pathway in Duchenne. Congratulations Pat Furlong and PPMD for hosting a great event!
-
-
This Pride month, we’re celebrating LGBTQIA+ scientists in STEM. Today we highlight Jemma Redmond, an intersex person whose innovation in 3D bioprinting revolutionized medical technology. Learn more about Jemma and other inspiring scientists here: https://lnkd.in/dtzcYFp
-
-
We’re heading to Orlando this week to join the Duchenne community in celebrating three decades of progress, community and resilience at PPMD’s 30th Annual Conference in Orlando, Florida! Thank you to Pat Furlong and the team at PPMD for your important work to support Duchenne families!
REGENXBIO Inc. has announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE® trial, and indicated that the company has confirmed an end-of-Phase II meeting is scheduled with the FDA at the end of July. REGENXBIO will be participating in PPMD’s 30th Annual Conference in Orlando, Florida during the “Research Row: Gene Therapy – Current and Evolving Landscape” session on Friday, June 28. If you haven't already registered to attend PPMD's 30th Annual Conference, register to attend virtually! https://lnkd.in/eV8Csijh
-
REGENXBIO announces expansion of AFFINITY DUCHENNE® trial to include a new cohort of younger patients. Learn more: https://lnkd.in/enTeuAAi
-
-
Today, REGENXBIO recognizes Juneteenth, also known as Freedom Day or Emancipation Day. This holiday commemorates the announcement of the abolition of slavery in Texas on June 19, 1865, two years after the Emancipation Proclamation was signed. It signifies the moment when the last enslaved African Americans learned of their freedom. On this day, we celebrate freedom, unity, and resilience. Learn more about Juneteenth from the National Museum of African American History and Culture: https://lnkd.in/gqvPZFF
-
-
REGENXBIO announces successful pre-BLA meeting with FDA to support accelerated approval pathway for RGX-121 for the treatment of MPS II. Learn more: https://lnkd.in/ejDeH4Pi
-
Similar pages
Browse jobs
Stock
RGNX
NASDAQ
20 minutes delay
$12.77
0.06 (0.472%)
- Open
- 12.86
- Low
- 12.46
- High
- 13.42
Data from Refinitiv
See more info on